During Wednesday’s trade, Shares of Facebook, Inc. (NASDAQ:FB), lost -0.38% to $106.69.
Facebook might be sending less traffic to publishers’ websites now than it did in January, or more traffic, or the same amount of traffic. It depends on who you ask, according to WSJ.
In recent years publishers have increasingly relied on Facebook to drive users to their websites, and some sites now receive as much as 90% of their traffic from the social network.
But that trend has some media executives nervous. Facebook could start to charge for the traffic it sends to their properties, they say, or give preference to content hosted directly on its network through features such as its Instant Articles initiative. WSJ Reports
Facebook, Inc. operates as a social networking company worldwide. It provides a set of development tools and application programming interfaces that enable developers to integrate with Facebook to create mobile and Web applications.
Shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), inclined 2.06% to $13.84, during its current trading session.
Lexicon Pharmaceuticals declared that top-line data from its TELECAST Phase 3 study showed results of telotristat etiprate in treating carcinoid syndrome in cancer patients with metastatic neuroendocrine tumors compriseent with the clinical benefit observed in its pivotal TELESTAR study. The TELECAST study was designed as a companion to TELESTAR primarily to provide additional safety exposure while further evaluating telotristat etiprate’s activity in carcinoid syndrome. TELECAST mostly enrolled patients treated with somatostatin analog (SSA) therapy, the current standard of care, with carcinoid syndrome characterized by less severe bowel movement frequency than those patients in the TELESTAR study, together with a smaller number of carcinoid syndrome patients not treated with SSA therapy.
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of human diseases. Its drug development programs comprise telotristat etiprate, an orally-delivered small molecule drug candidate, which is in Phase III clinical trials for the treatment of carcinoid syndrome.
Finally, Platform Specialty Products Corporation (NYSE:PAH), gained 1.56%, and is now trading at $13.02.
Platform Specialty Products Corporation, declared that the scheme of arrangement with Alent plc (“Alent”), dated August 17, 2015, counting the terms and conditions of Platform’s formerly-declared recommended offer to acquire all the issued and to be issued shares of Alent (the “Alent Acquisition”) has become effective.
As a result, MacDermid Performance Acquisitions Limited, a wholly-owned partner of Platform, has become the owner of all of the shares of Alent. The listing of Alent, and the admission to trading of Alent’s shares on the London Stock Exchange, are predictable to be cancelled on December 2, 2015.
Platform Specialty Products Corporation produces and sells specialty chemical products in the Americas, Asia, and Europe. The company’s Performance Materials segment manufactures and markets plating products that are used to plate holes; final finishes, which are used on printed circuit boards; circuit formation products to promote adhesion and form circuit patterns; oxides that are used in the fabrication of multilayer circuit boards; and pre-treatment and cleaning solutions.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.